Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.
Frequently asked questions
What sector does Hua Medicine (Shanghai) Ltd (HUMDF) operate in?
Hua Medicine (Shanghai) Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Hua Medicine (Shanghai) Ltd (HUMDF) current stock price?
As of the latest data, Hua Medicine (Shanghai) Ltd stock price is $0.30, with a previous close of $0.30.
What is Hua Medicine (Shanghai) Ltd (HUMDF) current market capitalization?
Hua Medicine (Shanghai) Ltd market cap is approximately 303.18 million.
What is Hua Medicine (Shanghai) Ltd (HUMDF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Hua Medicine (Shanghai) Ltd (HUMDF) EBITDA?
Hua Medicine (Shanghai) Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.05 million.
Does Hua Medicine (Shanghai) Ltd (HUMDF) pay dividends?
No. Hua Medicine (Shanghai) Ltd does not pay a dividend.
What is Hua Medicine (Shanghai) Ltd (HUMDF) beta (volatility) score?
Hua Medicine (Shanghai) Ltd has a beta of 0.808, meaning its volatility is roughly in line with the market.
